The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using chemo- and radio-therapy modestly increases the overall survival of patients; however, recurrence is inevitable, due to treatment resistance and lack of response to targeted therapies. GBM therapy resistance has been attributed to several extrinsic and intrinsic factors which affect the dynamics of tumor evolution and physiology thus creating clinical challenges. Tumor-intrinsic factors such as tumor heterogeneity, hypermutation, altered metabolomics and oncologically activated alternative splicing pathways change the tumor landscape to facilitate therapy failure and tumor progression. Moreover, tumor-extrinsic factors such as hypoxia and an immune-suppressive tumor microenvironment (TME) are the chief causes of immunotherapy failure in GBM. Amid the success of immunotherapy in other cancers, GBM has occurred as a model of resistance, thus focusing current efforts on not only alleviating the immunotolerance but also evading the escape mechanisms of tumor cells to therapy, caused by inter- and intra-tumoral heterogeneity. Here we review the various mechanisms of therapy resistance in GBM, caused by the continuously evolving tumor dynamics as well as the complex TME, which cumulatively contribute to GBM malignancy and therapy failure; in an attempt to understand and identify effective therapies for recurrent GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most tumors are poorly vascularized and hypoxic, which advances cancer progression and chemoresistance [70, 71].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · cited 9×
“Increasing mitochondrial ROS (mROS) has also been investigated to sensitize cells to RT. Post-radiation, the Hypoxia Inducible Factor 1α (HIF1α) target gene pyruvate dehydrogenase kinase (PDK) has been shown to be upregulated.”
BackgroundInfluentialSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Next, earlier studies have shown that TMZ is a direct cause of hypermutation in recurrent gliomas as seen by the accumulation of a TMZ-specific mutational signature in these tumors [39,62].”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668 · cited 1×
“Gliomas with methylated MGMT promoters are more sensitive to TMZ‐in‐ duced cytotoxicity with a longer median overall survival, as compared to patients whose tumors have unmethylated MGMT promoters [5,6].”
BackgroundVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · cited 2×
“TAMs are the dominant infiltrating immune population in glioma constituting around 30–40% of the total tumor volume [25,132,138].”
BackgroundSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033 · cited 1×
“The GBM TME attracts TAMs to the tumor and polarizes them to an anti-inflammatory or pro-tumorigenic ‘M2′-like state, thus current studies are aimed at inhibiting their recruitment or survival in the TME, allowing for their functional re-education to an anti-tumor ‘M1′-like state, or targeting the tumor using monoclon…”
Background
Cited by
Items 101–179 of 179
Zeng, J., Xu, C., Chen, L., Li, M., Yang, J., Nie, L., Zhang, M., Zhang, X., & Zhang, E. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106163 · Cited by 3
Liao, J., Duan, Y., Xu, X., Liu, Y., Zhan, C., & Xiao, G. (2025) · Discover Oncology · doi:10.1007/s12672-025-01863-2 · Cited by 3
The Aptamer bi-(AID-1-T) Synergizes with Radiation to Inhibit Proliferation of Human Glioma Cells
Pavlova, S., Rubetskaya, K., Fab, L. V., Savchenko, E., Samoylenkova, N. S., Revishchin, A. V., Ryabova, A. V., Antipina, N., Галкин, М. В., Голанов, А. В., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111442 · Cited by 3
Zhang, C., Hu, B., Wang, C., Hou, S., & Lin, N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1662351 · Cited by 3
“The tumor microenvironment (TME) comprises not only neoplastic cells but also astrocytes, tumor-associated macrophages (TAMs), and oligodendrocytes, which collectively in fl uence disease progression (3, 4).”
Self-citationGlioblastoma treatment with Boron Neutron Capture Therapy (BNCT): a revolutionary approach
Krishnamoorthy, K., & Prasad, M. (2026) · Holistic Integrative Oncology · doi:10.1007/s44178-026-00223-6 · Cited by 3
“Recurrent GBM frequently exhibits more aggressive behavior and is more resistant to traditional therapy [35].”
Alobaidi, A. M. A., & Kumeiko, V. (2026) · Cancers · doi:10.3390/cancers18030419 · Cited by 3
“…and extrinsic properties and molecular changes in glioma-associated brain cells, including macroglia, neurons, endothelial cells, pericytes, brain-resident microglia, and circulating monocytes, affect tumor resistance, angiogenesis, infiltration, and invasion that support glioma progression [95].”
The glioblastoma ecosystem: clonal evolution, heterogeneity, and therapeutic resistance
He, Y., Song, W., Li, S., & Guo, J. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1834106 · Cited by 3
“Temporal heterogeneity—the clonal dynamics under therapeutic pressure—is inextricably intertwined with the spatial dimension, collectively shaping a dynamically evolving ecosystem (Goenka et al., 2021; Qazi et al., 2022).”
Miller, D. M., Yadanapudi, K., Rai, V., Rai, S. N., Chen, J., Frieboes, H. B., Masters, A. H., McCallum, A. P., & Williams, B. J. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.06.010 · Cited by 3
Image Analysis Using Imaris 10.1 Machine Learning to Quantitate γH2AX Foci in U87 Cells
Planck, E., Teoli, D. F., & Yasui, L. S. (2024) · Microscopy and Microanalysis · doi:10.1093/mam/ozae044.201 · Cited by 3
Analysis of antitumor immunity in mouse glioma microenvironment through intercellular communication
Zhang, Y., Lu, F., Cai, N., Tang, L., Zhou, Y., Li, Y., Liu, K., Song, W., Li, K., & He, H. (2022) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_852_22 · Cited by 3
Bao, H., Ai, S., Wang, G., Yi, L., Lai, J., Wang, S., Lv, Z., Li, C., Liu, Q., Zhao, X., et al. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.108103 · Cited by 3
Role of Nucleobindin-2 in the Clinical Pathogenesis and Treatment Resistance of Glioblastoma
Lin, I.-C., Chang, C.-H., Chong, Y. B., Kuo, S.-H., Cheng, Y., Lieu, A., Tseng, T.-T., Lin, C., Tsai, H., & Kwan, A. (2023) · Cells · doi:10.3390/cells12192420 · Cited by 3
“However, more than 50% of patients show no response to TMZ, and almost all patients experience tumor recurrence eventually [5,33].”
BackgroundDoron, O., Wong, T., Ablyazova, F., Singha, S., Cavallaro, J., Ben-Shalom, N., D’Amico, R. S., Harshan, M., McKeown, A., Zlochower, A. B., et al. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04647-w · Cited by 2
“Despite decades of research, the prognosis of GBM remains extremely poor [15].”
BackgroundBielecka, A., Machnik, G., Linnebacher, C., Linnebacher, M., Stec-Grosman, K., & Obuchowicz, E. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2910364 · Cited by 2
D’arrigo, P., Dubois, M., Gil, J. S., Lassence, C., Hego, A., Brouwers, B., Lombard, A., Rogister, B., Neirinckx, V., Marielle, L., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201083 · Cited by 2
Wagner, K. K., Fotiou, M., Suo, S. J., Ramesh, S. A., Davis, R. A., & Yool, A. J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117613 · Cited by 2
Scuderi, S. A., Ardizzone, A., Mannino, D., Palermo, N., Luca, F. D., Catalfamo, A., Campolo, M., Esposito, E., & Paterniti, I. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70979 · Cited by 3
“Indeed, a major obstacle to successful therapy is the intrinsic and acquired resistance of GB cells to chemotherapy, particularly to TMZ [8].”
Advancing the Study of Glioblastoma Through 3D Tumor Models
Salmeron-Moreno, K., Buclez, J., Kim, C. D., Papisetty, K., McCaffery, T. D., Jacob, F., Kashlan, R., Duggireddy, H., Valiveti, K., Maldonado, J., et al. (2026) · Cancers · doi:10.3390/cancers18040668 · Cited by 2
Ammar, M. A. N., Dobiasová, S., Salaroglio, I. C., Hmissa, S., Missaoui, N., & Riganti, C. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00816-3 · Cited by 2
Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas
Gu, Q., Li, L., Yao, J., Dong, F.-Y., Gan, Y., Zhou, S., Wang, X., & Wang, X.-F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120103 · Cited by 4
“This is closely related to a number of factors, such as the tumor’s infiltrative growth, the inadequate surgical resection, and the development of chemo-radiotherapy resistance (5).”
BackgroundThe Pathogenic Roles of lncRNAs in Glioma
Moftakhar, A., Khoshnam, S. E., & Farzaneh, M. (2023) · Current Cancer Therapy Reviews · doi:10.2174/1573394719666230316112549 · Cited by 2
Zeryouh, A. Z., Wouters, R., Thirion, G., Vandenbrande, K., Vankerckhoven, A., Berckmans, Y., Bevers, S., Verbeeck, J., Keersmaecker, K. D., Coosemans, A., et al. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.07.003 · Cited by 3
Tsafa, E., Dimitriadis, K. S., Kalampoki, L., Papapetrou, P., Georgalis, P. A., Bozios, G., Sioka, C., Tsekeris, P. G., Kyritsis, A. P., Alexiou, G. Α., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12122793 · Cited by 2
PLGA Polymers and Doxorubicin for the Treatment of Malignant Gliomas in Adults: An Overview
Kudelkina, V. V., Gerasimov, A. D., Kosyreva, A. M., Алексеева, А. И., & Makarova, O. V. (2025) · The Open Medicinal Chemistry Journal · doi:10.2174/0118741045346445250111104531 · Cited by 2
Challenges and Emerging Strategies of Immunotherapy for Glioblastoma
Mao, M., Yao, L., Ma, X., & Xie, H. (2025) · ChemBioChem · doi:10.1002/cbic.202400848 · Cited by 3
Translational advancements in tumor vaccine therapies for glioblastomas
Jha, R., Spanehl, L., Chen, J., Gessler, F. A., Arnaout, O. M., Valdes, P. A., Choi, B. D., Peruzzi, P., Bernstock, J. D., & Chiocca, E. A. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf051 · Cited by 2
“10,11 Traditional chemotherapeutics and molecular therapies are only partially and transiently effective against certain subpopulations of the tumor.”
Riva, M., Bevers, S., Wouters, R., Thirion, G., Vandenbrande, K., Vankerckhoven, A., Berckmans, Y., Verbeeck, J., Keersmaecker, K. D., & Coosemans, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.17.448792 · Cited by 2
“invariably develops resistance mechanisms leading to the onset of recurrences with a median progression free survival (PFS) of seven months [3,4].”
BackgroundPractice Patterns for Managing Recurrent Glioblastoma Multiforme
Bajaj, J., Kedia, S., Sharma, A., Gupta, P., Ansari, M., Deora, H., Garg, K., Dash, C., Madhugiri, V. S., Das, K. K., et al. (2024) · Indian Journal of Neurosurgery · doi:10.1055/s-0043-1776359 · Cited by 1
Lee, H.-J., Lee, H.-K., Lee, S.-W., Son, Y.-W., Shin, J., & Kim, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333369 · Cited by 1
“Certain cancers with poor prognosis require rapid and personalized treatment due to difficulties in early diagnosis [2,3] or the recurrence of tumors that develop resistance to existing therapies and exhibit significant heterogeneity [4–6].”
Unveiling the prognostic and immunological role of IFI44 in glioma
Jin, D., Mao, L., Wu, Y., Tang, T., Yan, E., & Song, Z. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2593209 · Cited by 1
Restoring the glioblastoma tumor microenvironment by targeting C5a with the antagonist W54011
Oh, Y., Yoo, J., Lee, D., Ko, B., Hong, J., Moon, J. H., Kim, E. H., Chang, J. H., Kim, Y. C., & Kang, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-30853-1 · Cited by 1
Computational analysis of structural and dynamic impacts of TP53 missense mutations in glioblastoma
Hadi, N. A., Al-Mahmoodi, H., Alshamarti, I., Al‐Saffar, A. Z., Sulaiman, G. M., Mohammed, H. A., & Al‐Obaidi, J. R. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00678-z · Cited by 1
“The pathogenesis of GBM is intrinsically linked to an accumulation of somatic genetic mutations and epigen - etic aberrations (Khani et al. 2019), which drive neoplas - tic transformation and subsequent tumoral progression and therapeutic resistance (Goenka et al. 2021 ).”
Ullah, A., & Wu, Q. (2026) · Biomedical and Biotechnology Research Journal (BBRJ) · doi:10.4103/bbrj.bbrj_17_26 · Cited by 1
Selective and low-cost triterpene urea and amide derivatives of high cytotoxicity and selectivity
Brandes, B., Orlamünde, T. E., Hoenke, S., Denner, T. C., Al‐Harrasi, A., & Csük, R. (2022) · Results in Chemistry · doi:10.1016/j.rechem.2022.100610 · Cited by 1
CNN3 knockdown inhibits the proliferation, invasion and migration of gliomaPreprint
Xiao, X., Wang, Y., Han, X., Li, C., & Liang, P. (2022) · Research Square · doi:10.21203/rs.3.rs-1610265/v1
Lei, Z., Wang, Q., Zhu, J., Ye, J., Zhang, F., Feng, C., Jun, Q., Chun, L., Huairui, C., & Zhang, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-1679349/v1
A novel brain penetrant PDGFRα inhibitor HY-008 is effective against glioblastomaPreprint
Xu, C., Feng, H., & Sun, W. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.16.512412
“Tumor microenvironment, such as hypoxia is one of the major extrinsic factors contributing to GBM resistance [12].”
BackgroundBielecka, A., Machnik, G., Linnebacher, M., Linnebacher, C. S., & Obuchowicz, E. (2023) · Research Square · doi:10.21203/rs.3.rs-2782714/v1
Pérez-Aliacar, M., Ayensa-Jiménez, J., & Doblaré, M. (2024) · Lecture notes in computational vision and biomechanics · doi:10.1007/978-3-031-55315-8_28
Overcoming brain cancer treatment resistance: mechanisms and strategies
Mosoane, B., Marutha, T., Nonxuba, M., Sengupta, S., & Dlamini, Z. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-45495-0.00004-8
Izadi‐Najafabadi, S., McQuarrie, L., & Parmar, G. (2025) · Integrative Cancer Therapies · doi:10.1177/15347354251378069
“6 Given these challenges, there is growing interest in integrative oncology—an approach that combines conventional therapies with evidence-based complementary naturopathic strategies to enhance treatment efficacy, manage symptoms, and improve patient quality of life.”
Forsythe, D., Oliver, S. J., Valkovic, A., Lewthwaite, D., Uys, G., Koning, B., Eccles, D., Satgunaseelan, L., Hermans, I. F., Freytag, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.29.685449 · Cited by 1
Hindrance in immunotherapy resistant glioblastoma
Bhushan, R., Abubakar, M., Chavan, P. R., Pandey, R., Jamadade, M. S., Murti, K., & Kumar, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33910-3.00005-4
Targeting Glioblastoma Multiforme with intranasal delivery of milk-exosomal Mitoxantrone
Pereira, A. C. M. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/asap-rg55
Additional file 2 of Knockdown of ATRX enhances radiosensitivity in glioblastoma
Zhao, Y., Chen, Y., Liu, R., Liu, M., You, N., Zhao, K., Zhang, J., & Xu, B. (2024) · Figshare · doi:10.6084/m9.figshare.26736264
Additional file 1 of Knockdown of ATRX enhances radiosensitivity in glioblastoma
Zhao, Y., Chen, Y., Liu, R., Liu, M., You, N., Zhao, K., Zhang, J., & Xu, B. (2024) · Figshare · doi:10.6084/m9.figshare.26736261
Hu, S.-Q., Wang, J., Wang, J., Zeng, C., & Chen, R. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101979
Drug Repurposing and Overcoming the Blood-Brain Barrier for Glioblastoma
Konika, T. A., Shamsuzzaman, M., Uddin, M. E., Kim, J., & Hassan, M. A. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-2695-5.ch008
Prabhakar, D. (2025) · Oxford Journal of Student Scholarship · doi:10.65161/recz6ujfwnsvuuav6
Cassieri, P., Cirillo, F., Esposito, C., & Scanniello, G. (2025) · IEEE International Conference on Metrology for eXtended Reality, Artificial Intelligence and Neural Engineering (MetroXRAINE) · doi:10.1109/metroxraine66377.2025.11340182
“Gliomas [1], among the most aggressive primary brain tumors, pose significant clinical challenges due to their heterogeneous biological behavior and treatment resistance [2].”
Nisar, H., Sahibzada, K. I., Khan, A., Alwahaishi, S. S., & Agouni, A. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109357 · Cited by 1
Artificial intelligence applications in neuro-oncology
Slater, T., Vempati, P., & Baydoun, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00047-4
PRDM players in central nervous system cancers: State of the art and future perspectives
Zazzo, E. D., Donato, M. D., Rienzo, M., Casamassimi, A., Fiore, D., Proto, M. C., Gazzerro, P., & Abbondanza, C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105293
ELF3 drives glioblastoma multiforme progression through the regulation of MXRA8 expression
Wang, M., Bo, H., Chen, D., Mao, J., Miao, Z., & Wang, L. X. (2026) · Scientific Reports · doi:10.1038/s41598-026-46657-w
“Despite notable progress in surgical intervention, radiotherapy, and chemotherapy, these treatments yield only marginal improvements in patient survival, highlighting the urgent need for novel therapeutic approaches and a deeper understanding of its molecular mechanisms 6–8 .”
Bauer, J. A., Sysel, A. M., & Dunphy, M. (2026) · Oncoscience · doi:10.18632/oncoscience.654
“Tumor recurrence is inevitable, and therapeutic resistance is largely attributed to the tumor’s intrinsic heterogeneity, aggressive angiogenesis, and the presence of treatment-resistant glioma stem cells [3, 4].”
Herings, S. D. A., den Nieuwenhof, M. V., van der Kolk, A. G., Meijer, F. J. A., Scheenen, T. W. J., & Henssen, D. J. H. A. (2026) · Research Square · doi:10.21203/rs.3.rs-9377998/v1
Song, X., Xiao, Y., Liu, J., Wei, S., Tan, M., Chen, Y., & Yu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1811032
Self-citationShi, J., Song, Y., Shen, J., Zhang, X., Shao, C., Huang, Y., Feng, Z., Wan, Z., & Shen, J. (2026) · Research Square · doi:10.21203/rs.3.rs-9526893/v1
Pudełek, M., Pudełek, M., Przeniosło, J., Kędracka–Krok, S., Madeja, Z., & Czyż, J. (2026) · Cells · doi:10.3390/cells15100899
“Such findings underscore the urgent need to develop new therapeutic strategies for GBM [9,14,15].”
Smart nanomedicines for drug targeting to glioblastoma: Challenges and opportunities
Fatease, A. M. A., Barkat, M. A., Beg, S., Tandon, R., Srivastava, N., Shukla, R., Ansari, M. A., Hani, U., Fatima, F., & Singh, K. K. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108635
Lee, C. O., Park, S., Yun, Y., Choi, J. Y., Park, J.-S., Jeun, S., & Kim, Y. S. (2026) · Acta Neurochirurgica · doi:10.1007/s00701-026-06924-1
“The heterogeneity of GBM at the molecular level contributes significantly to its treatment resistance and recurrence [10].”
Zhang, C., Teng, D., Wang, C., Feng, R., Huang, X., Hu, B., Wang, Y., Lin, N., & Zhang, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1871988
“Given that immunity and in fl ammation are inextricably linked, and pro-tumor in fl ammation in GBM patients is likely to mediate their poor prognosis, we explored the role of TREM1 in in fl ammation using the seven macrogenes de fi ned earlier (29).”
InfluentialSelf-citationHipertermia y glioblastoma: abriendo nuevas fronteras en la neurooncología
Otero, N. B., Archibald Chester, O., Ch., M. C., Benjamín Oyarce, P., & Cecchi, B. V. (2026) · Revista chilena de neuro-psiquiatría · doi:10.4067/s0717-92272026000100062
Li, H., Zhao, J., Wang, H., Yuan, X., Zhang, L., Bian, C., Zhang, X., Chen, H., Xie, X., & Wang, F. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102370
Tsai, H.-P., Lee, T., Lin, H.-L., Lin, T.-W., Chang, W.-C., & Lin, C. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2694181
Deciphering LonP1’s role in glioblastoma: an alternative mechanism of treatment resistance
Jain, S., Ordaz, D. A., Lepe, J. J., Lomeli, N., Pham, J., Das, B., & Bota, D. A. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00145.2026
Fan, Y., Han, Q., Poddar, A., Luwor, R. B., Zhang, Y., Jayachandran, A., Dyett, B., Thang, S. H., Drummond, C. J., Zhai, J., et al. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c02571
Lu, W., Liu, Y., Wu, X., Ma, L., & Ma, H. (2026) · Journal of neurosurgery · doi:10.3171/2026.3.jns252582
Li, X., Hou, Q., Tang, Y., Wang, N., Zhong, C., Xu, L., & Wang, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1927290
Rosário, M. O. H. V., Fucase, T. M., Spencer, P. J., Sciani, J. M., Clarêncio, J., Rádis‐Baptista, G., Casais-e-Silva, L. L., & El-Bachá, R. D. S. (2026) · Journal of Applied Toxicology · doi:10.1002/jat.70409
Reddy, C. S., Nagisetty, D., Gaikwad, A., Mashozhera, N. T., Kumar, V., Lee, G., Harris, R. T., Hankins, G. R., & Reddy, U. K. (2026) · Molecules · doi:10.3390/molecules31203714
“Because of these problems, the treatment efficiency is reduced, and tumor recurrence is frequent, which in turn hinders the development of therapies that provide long-term relief [5,7].”
Ficus carica fruit extract induces mitochondria‐mediated apoptosis in C6 glial cells
Radhiga, T., Dhanabalan, K., Veeramani, C., Alsaif, M. A., & Al‐Numair, K. S. (2026) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.71099
Wang, S., Shi, Z., Zhu, C., Dai, D., Yang, X., Zhou, Z., Qiu, Q., Sun, W., Miao, Y., & Qiu, Y. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71024
“However, interpatient heterogeneity frequently leads to heterogeneous therapeutic responses to radiotherapy and chemotherapy, resulting in disease recurrence and metastatic progression despite multimodal interventions [6].”
Dunlap, S., Harvey, C. A., Elkholy, A., Gehrs, L., Mohamed, M., Khosravi, S. Z., Schanel, T. L., Murphy, J. M., Lim, S., Willey, C. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.08.757755
Sahu, P., Satapathy, T., Satapathy, A., & Satapathy, A. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02452-6
“Nano-phytomedicine platforms designed to cross the BBB via receptor-mediated transcytosissuch as transferrin-or peptide-functionalized nanoparticlesenable delivery of bioactive compounds directly into the tumor parenchyma [222].”
BindingDB (2023) · UC San Diego · doi:10.7270/q2jh3r74
Woźnicki, P., & Aebisher, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219878
Metadata
- Authors
- Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y.
- Affiliations
- Northwestern University (US)
- Corresponding author
- Cheng, Shi-Yuan
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-02-24
- Volume
- 10
- Issue
- 3
- Pages
- 484
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7995978
- OpenAlex
- W3132558808
- Cited by
- 169
- References
- 157
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 27 · 2023: 36 · 2022: 26 · 2021: 10
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Cancer Institute (CA221747, CA234799)
- National Institute of Neurological Disorders and Stroke (NS093843, NS095634, NS115403)
- The Lou and Jean Malnati Brain Tumor Institute at Northwestern Medcine (10031379)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glioblastoma, treatment resistance, tumor recurrence, tumor heterogeneity, hypermutation, cancer metabolomics, alternative splicing, hypoxia, tumor microenvironment, immunosuppression, immunotherapy resistance, tumor evolution
- MeSH terms
- Brain Neoplasms, Glioblastoma, Humans, Neoplasm Recurrence, Local, Drug Resistance, Neoplasm, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.